abbvie
(3)
The Chemist Who Wants to Build a Kinder Cancer Drug
He spent 25 years learning how cancer drugs fail. Now he is running a company built on the idea that the next generation can be safer, steadier, and easier to live with.
Andy Kidd
Andy Kidd is the chief executive officer of Tentarix Biotherapeutics, a San Diego company building conditionally active multispecific biologics for oncology and autoimmune disease through its Tentacles platform. A physician turned operator, he carries an unusual pairing of credentials - an M.D. from Oxford and a CFA - and spent over two decades crossing from the consulting room into the boardroom, from Boston Consulting Group to Baxter International to the helm of Nasdaq-listed Aptinyx, which he took public. He stepped into the Tentarix CEO seat in April 2024 to scale a science-heavy startup backed by partnerships with Gilead and AbbVie.
Lisa Olson
Lisa M. Olson, Ph.D., is a biopharmaceutical research leader who became CEO of Milan-based clinical-stage biotech Enthera Pharmaceuticals in January 2024, after years on its board and as chair of its Scientific Advisory Board. Across two decades in immunology drug discovery - 15 years at AbbVie/Abbott where she helped advance 15 molecules into the clinic including Rinvoq, plus roles at Pfizer and as Chief Scientific Officer of Magenta Therapeutics - she has built a career turning biology into medicine. At Enthera she is steering the clinical development of Ent001, a first-in-class antibody targeting the IGFBP3/TMEM219 pathway for inflammatory bowel disease and type 1 diabetes.